Zimmer Biomet Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZBH research report →
Range $93 – $140
Price Chart
About the company
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products.
- CEO
- Ivan Tornos
- IPO
- 2001
- Employees
- 17,000
- HQ
- Warsaw, IN, US
Get TickerSpark's AI analysis on ZBH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.13B
- P/E
- 25.90
- Fwd P/E
- 11.82
- PEG
- -11.69
- P/S
- 2.27
- P/B
- 1.54
- EV/EBITDA
- 11.62
- Div Yield
- 0.93%
- Gross Margin
- 69.68%
- Op Margin
- 15.11%
- Net Margin
- 8.96%
- ROE
- 6.05%
- ROIC
- 5.28%
Latest fiscal year · YoY change
- Revenue
- $8.23B+7.2%
- Gross Profit
- $5.07B-7.6%
- Op Income
- $1.36B
- Net Income
- $705.20M-22.0%
- EPS
- $3.56-20.0%
- OCF Growth
- +13.2%
- FCF Growth
- +28.9%
- 52W High
- $112.55
- 52W Low
- $79.12
- 50D MA
- $96.35
- 200D MA
- $92.83
- Beta
- 0.47
- RSI (14)
- 51
- Avg Volume
- 2.13M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Zimmer Biomet posted a solid Q3 with broad-based growth outside knees, raised full-year sales and EPS guidance, and said its Monogram robotics platform could come to market sooner than expected pending FDA approval.· November 4, 2026
- Total net sales were $2.63 billion, up 3.1% reported and 3.7% constant currency; management said excluding China distributor network consolidation, constant currency growth would have been 4.7%.
- Adjusted EPS was $1.90, flat year over year; adjusted gross margin was 71.7% (down 90 bps) and adjusted operating margin was 25.1% (down 140 bps).
- Hips grew 7% constant currency, S.E.T. grew 7.1%, and Technology & Data/Bone Cement/Surgical grew 13%, while knees declined 2.6% constant currency.
- Full-year 2026 guidance was raised to organic constant currency sales growth of 3% to 3.5% and adjusted EPS of $8.50 to $8.60; reported sales growth is now expected at 4.4% to 4.9%.
- Management said the U.S. sales-force transformation is ahead of plan, with over 75% of the sales force now fully dedicated, but knee pressure and China headwinds remain near-term drags.
Zimmer Biomet reported Q3 2026 total net sales of $2.63 billion, up 3.1% reported and 3.7% constant currency year over year. Adjusted EPS was $1.90, flat versus the prior year quarter, while GAAP diluted EPS was $1.00 versus $1.16 in Q3 2025. Adjusted gross margin was 71.7%, down 90 basis points year over year; adjusted operating margin was 25.1%, down 140 basis points. Cash flow was strong, with operating cash flow of $560 million and free cash flow of $372 million, both up about 34% year over year. For 2026, management raised organic constant currency sales growth guidance to 3% to 3.5% from 2.25% to 3.25%, raised adjusted EPS guidance to $8.50 to $8.60 from $8.47 to $8.59, and now expects reported sales growth of 4.4% to 4.9%. It also expects adjusted gross margin of around 72%, a full-year adjusted tax rate of about 18%, net interest and other nonoperating expenses of $300 million, and free cash flow growth of 9% to 11%.
Ivan Tornos framed the quarter as evidence that Zimmer Biomet is no longer a knee-dominated business, emphasizing that about two-thirds of the portfolio is now growing at upper-single-digit or double-digit rates. He highlighted strength in hips, S.E.T., and technology/data, along with Paragon 28’s continued growth, and said the company is becoming more diversified and more innovation-driven. His tone was constructive and confident, while still acknowledging that knees, especially in the U.S., still need work.
Paul Stellato said Q3 results were driven by strength in hips, S.E.T., and technology/data, offset by expected knee pressure. He cited 70 basis points of pricing pressure in the quarter, adjusted gross margin of 71.7%, adjusted operating margin of 25.1%, adjusted net interest and nonoperating expenses of $77 million, an adjusted tax rate of 17.6%, and fully diluted shares of 191.4 million, helped by $500 million of share repurchases in the first half and $79 million in Q3. He also highlighted operating cash flow of $560 million, free cash flow of $372 million, about $400 million in cash and cash equivalents, and reiterated that the company remains on track for roughly $1 billion in share repurchases in 2026.
Analysts pressed management on whether hips and S.E.T. growth is sustainable and when knees can return to growth. Tornos said the non-knee businesses have plenty of runway and that knee underperformance is largely commercial-execution related, with improvements expected as the sales-force transformation matures and as new robotics/innovation tools roll out. Questions on Monogram focused on commercialization and timing; management said the FDA filing is expected very soon and that the platform could enable a surgeon-guided fully autonomous launch in 1H 2027, earlier than the original 2028 expectation, but stressed approval is not yet in hand.
The bull case from this call is that Zimmer Biomet’s mix is broadening: hips, S.E.T., and technology/data are growing strongly, and management believes that strength is sustainable. The company also raised guidance, generated strong cash flow, and pointed to multiple future catalysts including Monogram, Paragon 28, and further benefits from the U.S. sales-force transformation.
The main risks remain knees and China. Management said U.S. knee performance is still under pressure from commercial-execution issues and a competitive market, and China will continue to weigh growth in the near term, contributing roughly 100 basis points of Q4 headwind and about 50 basis points for the full year. Gross margin also fell year over year because of higher manufacturing costs, and the company is still investing heavily in the sales-force transition and other growth initiatives, which limits near-term EPS leverage.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 189.25M
- Float Shares
- 188.92M
of shares held by institutions
934 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ZBH, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Oct 30, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 30, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 5, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 14, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 14, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jul 23, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jul 6, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 14, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jul 9, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jun 10, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | May 15, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 23.48M | ▲ 192.52K |
| Dodge & Cox | 22.73M | ▼ 1.39M |
| Blackrock, Inc. | 15.61M | ▼ 2.45K |
| Harris Associates L P | 12.74M | ▼ 221.91K |
| Vanguard Capital Management LLC | 12.48M | ▼ 155.07K |
| Capital International Investors | 10.86M | ▼ 1.32M |
| State Street Corp | 8.88M | ▲ 6.28K |
| Vanguard Portfolio Management LLC | 8.14M | ▼ 301.75K |
| Geode Capital Management, LLC | 5.39M | ▲ 37.91K |
| Price T Rowe Associates Inc | 4.80M | ▼ 3.20M |
| Invesco Ltd. | 4.13M | ▲ 148.93K |
| Primecap Management Co | 3.80M | ▼ 15.43K |
Held by 1,599 ETFs
Biggest fund positions in ZBH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Campbell Gary Craig | other | 1,218 |
| Oct 1, 26 | Campbell Gary Craig | other | 1,218 |
| Oct 1, 26 | Campbell Gary Craig | other | 2,368 |
| Oct 1, 26 | Campbell Gary Craig | other | 480 |
| Oct 1, 26 | Campbell Gary Craig | other | 932 |
| Oct 1, 26 | Campbell Gary Craig | other | 2,368 |
| Oct 1, 26 | Hatcher Brian Matthew | other | 0 |
| Oct 1, 26 | Hatcher Brian Matthew | other | 0 |
| Oct 1, 26 | Hatcher Brian Matthew | other | 0 |
| Oct 1, 26 | Hatcher Brian Matthew | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ZBH coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ZBH?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Jefferies London Healthcare Conference Transcript
seekingalpha.com · Nov 19
Zimmer Biomet Eyes Faster Growth in 2027, Targets Earlier Robotics Launch
marketbeat.com · Nov 19
Financial Contrast: Zimmer Biomet (NYSE:ZBH) and Artivion (NYSE:AORT)
defenseworld.net · Nov 11
Best Stocks for 2027: 3 Experts Name Their Top Picks
investorplace.com · Nov 11
Zimmer Biomet to Present at the Annual Jefferies Global Healthcare Conference in London
prnewswire.com · Nov 9
What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call
marketbeat.com · Nov 8
Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery
prnewswire.com · Nov 6
Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Term
zacks.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
